[go: up one dir, main page]

PE20001456A1 - Compuestos calcioliticos - Google Patents

Compuestos calcioliticos

Info

Publication number
PE20001456A1
PE20001456A1 PE2000000070A PE0000702000A PE20001456A1 PE 20001456 A1 PE20001456 A1 PE 20001456A1 PE 2000000070 A PE2000000070 A PE 2000000070A PE 0000702000 A PE0000702000 A PE 0000702000A PE 20001456 A1 PE20001456 A1 PE 20001456A1
Authority
PE
Peru
Prior art keywords
carbetoxyphenyl
cyane
phenoxy
naphthyl
propyl
Prior art date
Application number
PE2000000070A
Other languages
English (en)
Inventor
Lago Amparo Maria
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20001456A1 publication Critical patent/PE20001456A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES ARILO; X ES CN, NO2, Cl, F, H; Y ES Cl, F, Br, I, H; Q ES H, R1, SO2R1, R1COOR`1, TETRAZOL, CH2OH, ENTRE OTROS; R1 Y R1' SON H, ALQUILO C1-C4, O JUNTOS FORMAN UN HETEROCICLO DE 3-7 MIEMBROS; Ar ES FENILO, NAFTILO, HETEROARILO, HETEROARILO CONDENSADO. SON COMPUESTOS PREFERIDOS HIDROCLORURO DE N-[2R-HIDROXI-3-[2-CIANO-5-[2-CARBETOXIFENIL)FENOXI]]PROPIL]-1,1-DIMETIL-2-(2-NAFTIL)ETILAMINA; HIDROCLORURO DE N-[2R-HIDROXI-3-[2-CIANO-5-[4-CARBETOXIFENIL]FENOXI]PROPIL]-1,1-DIMETIL-2-(2-NAFTIL)ETILAMINA, ENTRE OTROS. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE CALCIO POR LO QUE PUEDE SER UTIL PARA EL TRATAMIENTO DE UN TRASTORNO DE LA HOMEOSTASIS ANORMAL DE LOS HUESOS COMO OSTEOSARCOMA, ENFERMEDAD PERIODONTAL, CURACION DE FRACTURAS, OSTEOARTRITIS, ARTRITIS REUMATOIDE, INCREMENTAR LOS NIVELES DE HORMONA PARATIROIDEA
PE2000000070A 1999-02-02 2000-02-01 Compuestos calcioliticos PE20001456A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11824099P 1999-02-02 1999-02-02

Publications (1)

Publication Number Publication Date
PE20001456A1 true PE20001456A1 (es) 2001-01-28

Family

ID=22377367

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000070A PE20001456A1 (es) 1999-02-02 2000-02-01 Compuestos calcioliticos

Country Status (24)

Country Link
US (1) US6417215B1 (es)
EP (1) EP1148876A4 (es)
JP (1) JP2002536330A (es)
KR (1) KR20010093285A (es)
CN (1) CN1346269A (es)
AP (1) AP2001002220A0 (es)
AU (1) AU3480200A (es)
BG (1) BG105847A (es)
BR (1) BR0007922A (es)
CA (1) CA2361589A1 (es)
CO (1) CO5251439A1 (es)
CZ (1) CZ20012797A3 (es)
EA (1) EA200100854A1 (es)
HK (1) HK1042036A1 (es)
HU (1) HUP0200121A3 (es)
ID (1) ID29533A (es)
IL (1) IL144470A0 (es)
MA (1) MA25379A1 (es)
NO (1) NO20013769L (es)
OA (1) OA11757A (es)
PE (1) PE20001456A1 (es)
SK (1) SK10982001A3 (es)
WO (1) WO2000045816A1 (es)
ZA (1) ZA200106298B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916956B2 (en) 2000-08-11 2005-07-12 Japan Tobacco, Inc. Calcium receptor antagonist
AU2002230579A1 (en) * 2000-10-25 2002-05-06 Smithkline Beecham Corp Calcilytic compounds
US6864267B2 (en) * 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
UY28089A1 (es) * 2002-11-26 2004-06-30 Smithkline Beecham Corp Compuestos calciliticos
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
SI1619180T1 (sl) * 2003-04-23 2010-04-30 Japan Tobacco Inc Antagonist CaSR
EP1630157A4 (en) 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
EP1964548A1 (en) * 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
JP5025795B2 (ja) * 2008-06-05 2012-09-12 旭化成ファーマ株式会社 スルホンアミド化合物及びその用途
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
WO2021029517A1 (en) * 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EA002984B1 (ru) * 1996-04-09 2002-12-26 Эн Пи Эс Фармасьютикалз, Инк. Кальцилитические соединения, фармацевтические композиции и способ скрининга кальцилитических соединений
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
EP1148876A4 (en) 2003-07-23
CN1346269A (zh) 2002-04-24
WO2000045816A1 (en) 2000-08-10
NO20013769L (no) 2001-09-26
AP2001002220A0 (en) 2001-09-30
KR20010093285A (ko) 2001-10-27
BR0007922A (pt) 2001-11-06
ID29533A (id) 2001-09-06
HUP0200121A3 (en) 2002-11-28
BG105847A (en) 2002-04-30
EA200100854A1 (ru) 2002-02-28
NO20013769D0 (no) 2001-08-01
EP1148876A1 (en) 2001-10-31
SK10982001A3 (sk) 2001-12-03
MA25379A1 (fr) 2002-04-01
CZ20012797A3 (cs) 2002-01-16
CA2361589A1 (en) 2000-08-10
OA11757A (en) 2005-07-19
JP2002536330A (ja) 2002-10-29
HUP0200121A2 (hu) 2002-05-29
HK1042036A1 (zh) 2002-08-02
CO5251439A1 (es) 2003-02-28
US6417215B1 (en) 2002-07-09
AU3480200A (en) 2000-08-25
ZA200106298B (en) 2002-10-18
IL144470A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
PE20001456A1 (es) Compuestos calcioliticos
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
BR0314338A (pt) Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma
KR930000117A (ko) 이미다졸 화합물, 이의 제조방법 및 용도
DE69532195D1 (de) Benzamidverbindung und ihre medizinische verwendung
CY1108367T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
BR0312801A (pt) inibidores de azaindol cinase
BR0311494A (pt) Novos indóis substituìdos
PE20021002A1 (es) Compuestos heterociclicos condensados
MXPA03001518A (es) Composicion y metodo para inhibir la agregacion plaquetaria.
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
PE43398A1 (es) Quinoxalinadionas
KR970069990A (ko) 페닐렌 유도체
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
PA8475401A1 (es) Compuestos de sulfonilbenceno como agentes antiinflamatorios/analgesicos
CY1107753T1 (el) 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ
PE20001640A1 (es) Compuestos dihetero sustituidos como inhibidores de metaloproteasas
BR0207645A (pt) Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
BR0207673A (pt) Compostos de carbamato para o uso no tratamento de dor
ID23954A (id) Tetrahidrogama-karbolin
BR0305708A (pt) Derivados de benzimidazol para o tratamento de disfunção sexual
DE69925270D1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
DK1648904T3 (da) N-sulfonylheterocyclopyrrolalkylaminforbindelser som 5-hydroxytryptamin-6-ligander
DE60221813D1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors

Legal Events

Date Code Title Description
FC Refusal